Leech Thrombomodulin-binding factor
Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
The reported thrombomodulin-binding activity is mechanistic only and does NOT establish clinical anticoagulant efficacy. No FDA-approved derivative exists; distinct from recombinant human thrombomodulin (ART-123/thrombomodulin alfa) developed by Asahi Kasei for DIC.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 11,000 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → thrombomodulin / thrombin / Protein C axis
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.